Effects of Xuezhikang Capsule(血脂康胶囊) on Blood Lipids,Platelet Activation and Coagulation-Fibrinolysis Activity in Patients with Hyperlipidemia

Objective: To investigate the effects of Xuezhikang capsule (XZK,血脂康胶囊) on blood lipids level, platelet activation and coagulation-fibrinolysis activity in patients with hyerlipidemia. Methods: Seventy-six patients of hyperlipidemia were randomly divided into two groups, the XZK group (n=38) treated with XZK 600mg, taken two times per day and the Simvastatin (SIM) group (n = 38) treated with SIM 20mg per day, with the treatment lasting 8 weeks for both groups. Levels of fasting serum lipids, including total cholesterol (TC), triglyceride (TG), high and low density lipoprotein cholesterol (HDL-C and LDL-C), plasma GMP-140, fibrinogen (FIB), tissue plasminogen activator (t-PA), plasminogen activator inhibitor type-1 (PAI-) and prothrombin time (PT) were all measured before and 8 weeks after treatment. Data were compared before and after treatment and also compared with those measured in 20 healthy subjects of control. Results: Before treantment the levels of TC, TG and LDL-C were obviously higher and HDL-C level was significantly lower in hyperlipidemia patients than those in healthy subjects (P<0.05 or P<0.01). After 4-8 weeks of XZK treatment, the levels of TC, TG, LDL-C and FIB and activities of GMP-140 and PAI-1 were obviously lowered (P<0. 05 or P<0. 01). But in the SIM group there was no obvious change in FIB (P>0.05), instead it showed obvious increase of HDL-C and decrease of TC and LDL-C after treatment (P<0.05 or P<0.01). Conclusion: XZK could inhibit platelet activity and improve coagulation-fibrinolysis function, besides its lipids lowering effect.

Effects of Xuezhikang (Red Yeast Rice) on Blood lipids, Hemorheology and the Expression of P65 and Tissue Factor in Atherosclerotic Rats

Objective: To observe the effects of Xuezhikang (red yeast rice) on blood lipids, blood rheology, and expression of P65 and tissue factor, and to explore the anti-atherosclerosis effect and related mechanisms of Xuezhikang (red yeast rice). Methods: 32 Wistar rats were randomly divided into normal control group, Xuezhikang treatment group, lovastatin treatment group and atherosclerosis model group (8 in each group). Blood lipids, blood rheology, malondialdehyde (MDA), total antioxidant capacity (T-AOC), and expression of aortic tissue factor (TF) and P65 were measured in each group. Results:(1) Both Xuezhikang and lovastatin could reduce blood lipid levels, but there was no significant difference between the two groups;(2) Both Xuezhikang and lovastatin can improve the hemorheology of atherosclerotic rats, but the difference between the two groups is not significant;(3) Compared with lovastatin, Xuezhikang inhibited the expression of TF and P65 in aorta of rats with atherosclerosis;(4) Compared with lovastatin, the Xuezhikang group had lower MDA levels and higher T-AOC. Conclusion: Xuezhikang can improve blood lipid levels and hemorheology in rats with atherosclerosis. Compared with lovastatin, Xuezhikang has stronger effects on inhibiting oxidative stress and down-regulating the expression of tissue factor and P65.

Changes of Lipid Profile and C-Reactive Protein after Withdrawal of Xuezhikang,an Extract of Cholestin,in Patients With Stable Angina Pectoris

Objectives In addition to its lipid-lowering properties, statin decreases the level of C-reactive protein （CRP） resulting in reduction of cardiovascular events. However, information about discontinuation of statin therapy in stable cardiac patients is limited. This was a prospective cohort study to explore whether withdrawal of statin treatment could result in rebound of inflammation in patients with stable angina pectofis in a short-term course. Methods and Results 75 patients with stable angina pectoris were randomly divided into three groups： ① Pretreatment with Xuezhikang （XZK, an extract of cholestin） for 6 weeks and then replaced by placebo; ②Treatment with XZK throughout the study; ③ Placebo. Lipid levels, highly sensitive CRP （hs-CRP） and serum cardiac troponin T （cTnT） were assessed before receiving the XZK therapy, 1 day before discontinuation of XZK, and on day 1, 2, 3, 7 and 14 after discontinuation of XZK, respectively. At day 14 after discontinuation of XZK therapy, total cholesterol, LDL-C and triglyceride significantly increased, whereas HDL-C level significantly decreased. The median level of hs-CRP increased significantly from the second day after withdrawal of XZK therapy. There was a prominent rebound of hs-CRP concentration 3 days after discontinuation of XZK therapy. 7 to 14 days after discontinuation of XZK therapy, the hs-CRP concentration declined to a similar level as in the placebo group. Elevated eTnT level did not occur throughout the study course in either guroup Conclusios Short-term discontinuation of statin therapy could induce a rapid rebound phenomenon of inflammatory response independently of changes of lipid parameters. However, it was not enough to induce myocardial injury in this cohort of patients with stable angina peetoris.

Effects of XUEZHIKANG on Oxidized Low Density Lipoprotein,C - Reactive Protein, Fibrinogen in Unstable Angina Pectoris Patients

Objectives To study the effects of XUEZHIKANG on lipid modulating and the level of oxidized low density lipoprotein(OX - LDL), C -reactive protein(CRP), fibrinogen(FIB) in serum. Methods XUEZHIKANG was given to patients with unstable angina pectoris and hyperlipidemia at a dose of 0. 6 gram bid for 2 months and with half -dose for another 2 months. Vitamin E was given to unstable angina pectoris patients with normal lipid at the dose of 0. 1 gram bid for 4 months respectively. Then compared the level of lipid and OX - LDfL, CRP, FIB in serum at beginning, first - month and second -month. Results XUEZHIKANG can reduce the serum level of total cholesterol, low density lipoprotein in 1 month , and gained better effect in 2 months. It can also reduce triglyceride and increase high density lipoprotein in 2 months. Compared with vitamin E XUEZHIKANG can reduce the level of OX - LDL, CRP, FIB significantly after treatment for 2 months. Conclusions XUEZHIKANG has significant effect in lipid modulating , and it can also inhibit the development of inflammation in coronary plaque.

Effect of Xuezhikang Capsule(血脂康胶囊)on Serum Tumor Necrosis Factor-αand Interleukin-6 in Patients with Nonalcoholic Fatty Liver Disease and Hyperlipidemia

Objective：To evaluate the effect of Xuezhikang Capsule（血脂康胶囊） on the serum levels of inflammatory factors such as tumor necrosis factor-α（TNF-α） and interleukin-6（IL-6） in patients with nonalcoholic fatty liver disease（NAFLD） and hyperlipidemia,and to explore whether it has anti-inflammatory effect.Methods：A total of 84 patients were randomly assigned to two groups with stratified block randomization, the treatment group（42 cases） and the control group（42 cases）.They were treated with Xuezhikang Capsule and polyene phosphatidylcholine capsule for twenty-four weeks,respectively.The changes in serum TNF-αand IL-6 were measured by enzyme linked immunosorbent assay before treatment and at the 12th and 24th week. Results：Compared with those before treatment,the serum levels of TNF-αand IL-6 significantly decreased in both groups after treatment（P〈0.01）.There was no significant change between the two groups for the treatments at different time points（P〉0.05） and between the two groups for treatments at the same time points （P〉0.05）.Conclusion：Xuezhikang Capsule can inhibit the serum inflammatory factor in patients with NAFLD and hyperlipidemia.

Effects of Combined Therapy of Xuezhikang Capsule(血脂康胶囊)and Valsartan on Hypertensive Left Ventricular Hypertrophy and Heart Rate Turbulence

Objective：To observe the effect of combined therapy with Xuezhikang Capsule（血脂康胶囊,XZK） and Valsartan on left ventricular hypertrophy（LVH） and heart rate turbulence（HRT） in hypertensive patients. Methods：Ninety primary hypertensive patients with LVH were randomly assigned to three groups.Basic treatment,including aspirin,β-blockers,calcium antagonists,etc.were administered to all patients.Additionally, Valsartan（VS,80 mg once a day） was given to the 30 patients in the VS group.Valsartan（in the same dosage） and XZK（600 mg,twice a day） were given to the 32 patients in the Chinese medicine（CM） group,while none was given to the 28 patients in the control group.The therapeutic course lasted for 24 months.Changes in left ventricular mass index（LVMI） measured by cardiac ultrasonic indices,HRT parameters,including the original heart rate（TO） and slope coefficient（TS）,systolic and diastolic blood pressures（SBP and DBP）,as well as blood cholesterol level（TC） were measured before and after treatment.Results：After treatment,TO and LVMI were lowered,while TS increased in both the VS group and the CM group（P〈0.01）,but changed insignificantly in the control group.Significant differences between the CM group and the control group were shown in terms of TO,LVMI,SBP,DBP and TS（P〈0.01）;and between the CM group and the VS group in terms of TO,LVMI and TS（P〈0.01）.Moreover,HRT parameters showed an evident correlation with LVMI（r=0.519-0.635,P〈0.01）. Conclusion：Combined therapy with XZK and Valsartan can improve hypertensive LVH and HRT parameters, and lessen the damage on the autonomous nervous system.

Effects of Xuezhikang(血脂康) and Pravastatin on Circulating Endothelial Progenitor Cells in Patients with Essential Hypertension

Objective:To investigate the impacts of Xuezhikang(血脂康,XZK)or pravastatin combined with antihypertensive drugs on circulating endothelial progenitor cells(CEPCs)in essential hypertensive (EH)patients.Methods:Eighty-eight EH patients were enrolled into the study and randomly assigned to the antihypertensive drug treatment group(ATH group,29 cases),the pravastatin treatment group(PRA group,29 cases)and the Xuezhikang treatment group(XZK group,30 cases).Patients in the 3 groups were treated with routine antihy...

血脂康联合阿利西尤单抗对他汀类药物不耐受动脉粥样硬化性心血管疾病患者LDL-C达标率和其他血脂指标影响

目的探讨对他汀类药物不耐受动脉粥样硬化性心血管疾病患者应用血脂康联合阿利西尤单抗的价值。方法选取2022年6月—2023年9月收治的对他汀类药物不耐受的动脉粥样硬化性心血管疾病80例,根据治疗方法不同将其分为研究组和对照组2组各40例。研究组给予血脂康联合阿利西尤单抗治疗,对照组给予阿利西尤单抗治疗。比较2组治疗前和治疗4、8、12周后低密度脂蛋白胆固醇(LDL-C)、其他血脂指标[总胆固醇、高密度脂蛋白胆固醇(HDL-C)和三酰甘油],治疗4周后LDL-C达标率和降低>50%达标率,以及治疗期间不良反应发生情况。结果与治疗前比较,治疗4、8和12周后2组LDL-C均降低,且治疗4、8和12周后研究组LDL-C低于对照组(P<0.05)。与治疗前比较,治疗4、8和12周后2组总胆固醇和三酰甘油均降低,HDL-C升高(P<0.05)。治疗4、8和12周后,研究组总胆固醇较对照组降低(P<0.05)。治疗4周后,研究组LDL-C达标率和降低>50%达标率高于对照组(P<0.05)。治疗期间,2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论血脂康联合阿利西尤单抗应用于他汀类药物不耐受动脉粥样硬化性心血管疾病患者利于改善血脂水平,提高LDL-C达标率,且安全性较高。

Xuezhikang(血脂康) Reduced Renal Cell Apoptosis in Streptozocin-Induced Diabetic Rats through Regulation of Bcl-2 Family

Objective： To investigate the effect of Xuezhikang（血脂康, XZK） on renal cell apoptosis in diabetic rats and the possible mechanism. Methods： Sixty-six rats were randomly divided into 3 groups： the normal, model and XZK groups. In each group, the rats were further randomly divided into 3-month and 6-month subgroups, respectively. Diabetes of rats was induced by a single intraperitoneal injection of 1% streptozocin at 60 mg/kg body weight. Rats in the XZK group received gastric perfusion of XZK（1200 mg/kg body weight） everyday for 3 or 6 months, while rats in the normal and model groups received equal volume of saline. Twenty-four hours＇ urine was collected for urinary albumin excretion（UAE） measurement. Periodic acid-Schiff（PAS） and Masson＇s trichrome staining were used for saccharides and collagen detection. Cell apoptosis of renal cortex was investigated by Td T-mediated d UTP nick end labeling（TUNEL） staining. Bax and Bcl-2 expressions were detected by immunohistochemistry and Western blot, respectively. Cytochrome C（Cyt C） and caspase-9 concentration were detected by Western blot. Results： Compared with the model group, XZK treatment could significantly decrease the kidney hypertrophy index, 24 h UAE, renal cell apoptosis, cytoplasmic Cyt C level and active caspase-9 level, as well as suppress the increment of Bax and up-regulate the expression of Bcl-2, leading to the suppression of Bax/Bcl-2 ratio at 3 and 6 months（P〈0.05 or P〈0.01）. Moreover, XZK treatment could alleviate the deposition of PAS-stained saccharides and Masson＇s trichromestained collagen to different extent. Conclusions： Renal cell apoptosis was observed in diabetic kidney, in which mitochondrial apoptotic pathway might be involved. XZK treatment could attenuate pathological changes in diabetic kidney and reduce renal cell apoptosis, probably via the suppression of Bax/Bcl-2 ratio, which lead to inhibition of Cyt C release and following caspase-9 activation.

Nrf2在脑出血后血肿清除及脑保护中的作用及机制

脑出血(ICH)是一种具有高发病率、高死亡率、高致残率的脑血管病。出血后形成的血肿是脑出血后脑损害的始动因素,早期有效清除血肿成分对于预防及减轻早期脑出血后脑损伤至关重要。目前针对ICH的临床治疗手段相对有限,近期的临床前试验取得了令人兴奋的结果,其中一个引人关注的新靶点是核因子E2相关因子2(Nrf2)。Nrf2是一种转录因子,可能通过不同通路激活细胞修复机制发挥神经保护作用。它在疾病治疗中的潜力引起了广泛的研究兴趣。本文总结了Nrf2及其激动剂在脑出血后血肿清除及脑保护中的作用及机制。

Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans

Background: Previous studies have clearly demonstrated that XueZhiKang (XZK), an extract of cholestin, can decrease low-density lipoprotein cholesterol (LDL-C) and cardiovascular events. However, the mechanism of the effects of XZK on athero-sclerosis (AS) in humans has been reported less frequently. In the present study, we investigated the impact of XZK on lipoprotein subfractions, oxidized LDL (oxLDL), and interleukin-6 (IL-6). Methods: From October 2015 to July 2016, 40 subjects were enrolled in this study. Of them, 20 subjects with dyslipidemia received XZK 1200 mg/day for 8 weeks (XZK group); 20 additional healthy subjects who did not receive therapy acted as controls. The plasma lipoprotein subfractions, oxLDL, and IL-6 were examined at baseline and again at 8 weeks. Results: Data showed that XZK could significantly decrease not only plasma LDL-C levels (87.26 ± 24.45 vs. 123.34 ± 23.99, P<0.001), total cholesterol (4.14 ± 0.87 vs. 5.08 ± 1.03, P<0.001), triglycerides (0.95 ± 0.38 vs. 1.55 ± 0.61, P<0.05), and apolipoprotein B (1.70 ± 0.35 vs. 1.81 ± 0.72, P<0.05), but also oxLDL (36.36 ± 5.31 vs. 49.20 ± 15.01, P<0.05) and IL-6 (8.50 ± 7.40 vs. 10.40 ± 9.49, P<0.05). At the same time, XZK reduced the concentration of small LDL-C (1.78 ± 2.17 vs. 6.33 ± 7.78, P<0.05) and the percentage of the small LDL subfraction (1.09 ± 1.12 vs. 3.07 ± 3.09, P<0.05). Conclusions: Treatment with 1200 mg/day XZK for 8 weeks significantly decreased the atherogenic small LDL subfraction and reduced oxidative stress and inflammatory markers, in addition to affecting the lipid profile, suggesting multiple beneficial effects in coronary artery disease.

Short-andLong-Term Effects of Xuezhikang(血脂康),An Extract of Cholestin,on Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels

Objective：To investigate the short- and long-term effects of Xuezhikang（血脂康,XZK）,an extract of Cholestin,on proprotein convertase subtilisin/kexin type 9（PCSK9） level.Methods：Thirty rats were randomly divided into three groups and were given saline,XZK 1,200 mg/kg or lovastatin 10 mg/kg respectively by daily gavage for 3 days（n=10 for each）.Sixteen patients without previous iipid-lowering drug treatment for dyslipidemia received XZK 1,200 mg daily for 8 weeks.Fasting blood samples and liver tissue were collected at day 3 for rats,while the blood samples were obtained at baseline and week 8 from patients.The serum PCSK9 and lipid profile were measured.The expression of hepatic low density lipoprotein（LDL） receptor and sterol regulatory element binding protein 2（SREBP-2） were measured by real time-PCR.Results：PCSK9 levels in rats were significantly increased in the XZK and lovastatin groups（P=0.002,P=0.003 vs.control） at day 3,while no significant differences were found in the levels of lipid parameters.PCSK9 levels in patients increased by34%（P=0.006 vs.baseline） accompanied by total cholesterol and LDL-cholesterol decreased by 22%and 28%（P=0.001,P=0.002 vs.baseline）.The hepatic mRNA levels of LDL-receptor and SREBP-2 were significantly increased in the XZK and lovastatin groups.Conclusion：XZK has significant impact on PCSK9 in a short- and long-term manner in both rats and humans.Moreover,the data indicated that as lovastatin,XZK increased PCSK9 levels through SREBP-2 pathway.

Protective effect of Xuezhikang capsules in rats with acute myocardial ischemia reperfusion injury

Background Recent researches have found that stains can improve acute myocardial ischemia reperfusion injury which is achieved by inhibiting inflammatory reaction.Xuezhikang is extracted from red rice,a tailor-made Chinese crude drug.Main component of Xuezhikang that can inhibit blood-fat is statins.Methods Forty healthy SD rats （half male and half female,200 g or so） were randomly divided into four groups：A：normal control;B：sham operation;C：MIR group;D：Xuezhikang group.The acute myocardial ischemia reperfusion injury model was produced.Infarct sizes,MYO,CK-MB,cTnI,IL-10 and IL-18 were detected after reperfusion.Results Compared with C and D group,in A and B group,infarct size were increased significantly （P 0.01）,the level of serum MYO,CK-MB,cTnI were increased significantly （P 0.01）,the level of IL-10 were decreased significantly （P 0.01） and IL-18,CRP were increased significantly （P 0.01）.Compared with C group,infarct size were decreased significantly （P 0.05）,the level of serum MYO,CK-MB and cTnI were increased significantly（P 0.05）,the level of IL-10 were increased significantly （P 0.05） and IL-18 were decreased significantly （P 0.05）.The level of IL-10 and IL-18 were no difference between A and B group.Conclusion The application of Xuezhikang capsules on rats before the operation of myocardial ischemia reperfusion can lessen inflammatory reaction and reduce infarct sizes and protect acute myocardial ischemia reperfusion.

血脂康胶囊联合阿托伐他汀治疗颈动脉粥样硬化患者的效果

目的:观察血脂康胶囊联合阿托伐他汀治疗颈动脉粥样硬化患者的效果。方法:回顾性分析2021年9月至2023年3月该院收治的120例颈动脉粥样硬化患者的临床资料,按照治疗方法不同分为观察组与对照组各60例。对照组口服阿托伐他汀钙片治疗,观察组在对照组基础上联合血脂康胶囊治疗。比较两组临床疗效,治疗前后颈动脉内膜中层厚度(IMT)、斑块面积、血脂[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)]水平,以及不良反应发生率。结果:观察组治疗总有效率为95.00%(57/60),高于对照组的83.33%(50/60),差异有统计学意义(P<0.05);治疗后,观察组颈动脉IMT、斑块面积均小于对照组,TC、TG、LDL-C水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:血脂康胶囊联合阿托伐他汀治疗颈动脉粥样硬化患者可提高治疗总有效率,缩小颈动脉IMT和斑块面积,降低TC、TG、LDL-C水平,效果优于单用阿伐他汀治疗。

血脂康胶囊联合氨氯地平与阿托伐他汀钙治疗高血压合并冠心病患者的效果

目的:观察血脂康胶囊联合氨氯地平与阿托伐他汀钙治疗高血压合并冠心病患者的效果。方法:选取2021年3月至2023年2月该院收治的150例高血压合并冠心病患者进行前瞻性研究,按照随机数字表法将其分为研究组与对照组各75例。对照组采用阿托伐他汀钙片联合磺酸氨氯地平片治疗,研究组在对照组基础上联合血脂康胶囊治疗,比较两组临床疗效,治疗前后心功能指标[左心室收缩期末内径(LVESD)、左心室舒张期末内径(LVEDD)]水平、心肌损伤标志物[肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTnI)、氨基末端脑钠肽前体(NT-proBNP)]水平、脂代谢指标[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]水平,以及不良反应发生率。结果:研究组治疗总有效率为92.00%(69/75),高于对照组的80.00%(60/75),差异有统计学意义(P<0.05);治疗后,两组LVESD、LVEDD水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组cTnI、CK-MB、NT-proBNP水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组TC、TG、LDL-C水平均低于治疗前,且研究组低于对照组,两组HDL-C水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:血脂康胶囊联合氨氯地平与阿托伐他汀钙治疗高血压合并冠心病患者可提高治疗总有效率,改善脂代谢指标水平,降低心功能指标和心肌损伤标志物水平,其效果优于阿托伐他汀钙片联合磺酸氨氯地平片治疗。

Effect of"Natural Polypill",Xuezhikang on Serum Cholesterol Metabolism Markers in Early Menopausal Women with Hypercholesterolemia

Objective:To analyze the effect of Xuezhikang on the markers of the serum lipid levels of cholesterol synthesis and absorption in early menopausal women with hypercholesterolemia,and preliminarily explore its lipid-lowering mechanism.Methods:A total of 90 early menopausal women with hypercholesterolemia were enrolled from December,2014 to May,2016 from Beijing Anzhen Hospital,Capital Medical University,who were randomly allocated to receive Xuezhikang(1200 mg/d,orally)or atorvastatin(10 mg/d,orally)according to a random number table.Serum levels of some related biomarkers,including cholesterol synthesis markers(squalene,dihydrocholesterol,dehydrocholesterol,and lathosterol),and absorption markers(campesterol,stigmasterol,and sitosterol)as well as safety indices were obtained at baseline and after 8 weeks of the intervention.Results:Eight weeks after treatment,both Xuezhikang and atorvastatin significantly reduced the levels of total cholesterol,triglycerides,low density cholesterol compared to baseline(all P<0.01).Xuezhikang significantly reduced the levels of squalene,dehydrocholesterol and lathosterol compared to baseline(all P<0.01),but atorvastatin only significantly reduced the level of squalene(P<0.01),compared to baseline.All cholesterol absorption markers showed no significant differences before and after treatment(P>0.05),however,a more obvious downward trend was shown in the Xuezhikang group.In addition,all the safety indices showed no significant differences between the two groups.Although the creatinekinase level in the Xuezhikang group was significantly higher,it remained within the safe range.Conclusions:Xuezhikang may have more comprehensive effects on the markers of cholesterol synthesis and metabolism in early menopausal women with hypercholesterolemia through ergosterol and flavonoids in its"natural polypill."

Modulatory effect on dyslipidemia and anti-atherosclerotic function of Xuezhikang in newly diagnosed type 2 diabetes patients

The modulatory effect of Xuezhikang on dysli-pidemia and the preventive effect on atherosclerosis in newly diagnosed type 2 diabetic patients were studied.A prospective clinical trial was conducted to test the effec-tiveness of Xuezhikang in selected 201 newly diagnosed type 2 diabetic patients.All patients were randomly divided into two groups:108 with Xuezhikang therapy and 93 without Xuezhikang therapy.The mean follow-up period was 22 months.The blood glucose and blood pressure of all patients were under control.Serum levels of total cholesterol(TC),triglyceride(TG),and low density lipoprotein cholesterol(LDL-C)were significantly low-ered and their decreased percentages were significantly higher in Xuezhikang therapy group(P<0.05).The num-ber of patients with arteria iliaca intima thickening was significantly lower in group of Xuezhikang therapy(P=0.024).With stepwise multivariate logistic regression analysis,the decreased percentage of TG was significantly and independently related with the decreased number of patients with arteria iliaca intima thickening(P=0.005).The study demonstrates that Xuezhikang therapy is effec-tive on modulating dyslipidemia in newly diagnosed type 2 diabetes patients,and may be related with the improve-ment of early atherosclerosis.

血脂康胶囊联合普伐他汀钠片对老年急性心肌梗死后慢性心力衰竭患者的应用效果及对神经内分泌因子的影响

目的探讨血脂康胶囊联合普伐他汀钠片对老年急性心肌梗死后慢性心力衰竭患者的应用效果及对神经内分泌因子的影响。方法选取2022年6月—2023年4月北京市垂杨柳医院收治的80例急性心肌梗死后慢性心力衰竭患者作为对象进行研究,应用抽签法将其分为三组,即对照组(n=30)、观察A组(n=25)和观察B组(n=25)。给予对照组患者常规治疗,观察A组患者在对照组治疗的基础上增加普伐他汀钠片口服,观察B组患者在观察A组基础上增加血脂康胶囊口服。对比三组患者临床疗效,血浆B型利钠肽(BNP)、血浆肾素(PRA)、醛固酮(ALD)以及血管紧张素Ⅱ(AngⅡ)相关神经内分泌因子水平与左心室射血分数(LVEF)、左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)相关心功能指标变化。结果观察B组总有效率明显高于对照组和观察A组,观察A组高于对照组(P<0.05);治疗后三组患者BNP、PRA、ALD、AngⅡ水平均降低,且观察B组低于对照组和观察A组,观察A组低于对照组(P<0.05);治疗后三组患者LVEF升高,观察B组高于对照组和观察A组,观察A组高于对照组,LVESV、LVEDV降低,观察B组低于对照组和观察A组,观察A组低于对照组(P<0.05)。结论血脂康胶囊联合普伐他汀钠片对老年急性心肌梗死后慢性心力衰竭具有显著治疗效果,且能够降低神经内分泌因子水平,提升心功能,值得临床应用。

The effects of Xuezhikang on vascular remodeling and aortic fibers in spontaneously hypertensive rats

Background Xuezhikang is a traditional Chinese medicine for the therapy of patients with cardiovascular diseases. However, the effect of Xuezhikang on vascular remodeling and aortic fibers in spontaneously hypertensive rats remains unclear. Methods Thirty spontaneously hypertensive rats（SHRs） aged 8 weeks were randomized into three groups： SHRs control group（SHRs group, n = 10）, group treated with low dose Xuezhikang（XZK-L,20 mg/kg/d, n = 10） and group treated with high dose Xuezhikang（XZK-H, 200 mg/kg/d, n = 10）. The normal group was comprised of ten Wistar-Kyoto（WKY） rats of the same age. While under pentobarbital anesthesia, in vivo aortic stiffness was determined by a pulse wave velocity（PWV） technique and measured locally in the descending thoracic aorta by Doppler ultrasound echocardiography. Fixed tissues were sectioned and stained with hematoxylin and eosin, masson trichrome, aldehyde-fuchsin and Gordon-Sweets stain. Results The PWV, thicknesses of the aortic wall, wall-to-lumen（W/L） ratio, elastic fibers thicknesses and collagen volume fraction were measured. XZK-L and XZK-H groups were observed to be significantly greater than those in the normal group（P 〈 0.01）. The levels of PWV, W/L ratio and collagen fibers were observed to be significantly reduced in the XZK-H group when compared with the control group（P 〈 0.05）. There was no significance in reticular fiber distributing between the XZK-treated group and SHR group. The reticular fibers in SHR rats were obviously more than those of WKY rats. Conclusion The hypertensive vascular remodeling is associated with changes of elastic fibers and collagen and reticular fibers. Xuezhikang improves hypertensive vascular remodeling by repairing the elastic fibers and inhibiting the levels of collagen.

血脂康胶囊联合非诺贝特胶囊治疗高脂血症性胰腺炎的疗效观察

目的探究血脂康胶囊联合非诺贝特胶囊治疗高脂血症性胰腺炎的疗效。方法以回顾性分析法选择2018年1月至2020年10月临沂市人民医院收治的102例高脂血症性胰腺炎患者为本次研究对象,并根据入院时间对患者进行分组处理,2018年1月至2019年5月入院的患者为对照组、2019年6月至2020年10月入院的患者为观察组,每组各51例。对照组给予非诺贝特胶囊治疗,观察组在对照组治疗基础上加施血脂康胶囊,疗程2周。比较两组患者的疗效,并比较治疗后两组患者血液流变学指标[全血高切黏度(HBV)、全血低切黏度(LBV)、血浆黏度(PV)、红细胞聚集指数(Arbc)]、炎症因子[巨噬细胞移动抑制因子(MIF)、核因子κB(NF-κB)、可溶性白细胞介素-2受体(sIL-2R)、白细胞介素-32(IL-32)]、血脂代谢指标[游离脂肪酸(FFA)、载脂蛋白B(ApoB)、甘油三脂]变化。评估两组患者的急性生理学和慢性健康状况评价(APACHEⅡ)量表评分,统计两组患者住院时间。结果观察组治疗总有效率为96.08%,高于对照组(76.47%),差异有统计学意义(P<0.05)。治疗后,观察组HBV、LBV、PV、Arbc水平分别为(2.28±0.48)mPa·s、(3.01±0.53)mPa·s、(0.79±0.11)mPa·s、1.42±0.13,均低于对照组[(4.12±0.70)mPa·s、(4.12±0.70)mPa·s、(1.04±0.20)mPa·s、2.02±0.27],差异均有统计学意义(P<0.05)。治疗后,观察组MIF、NF-κB、sIL-2R、IL-32水平分别为(23.15±4.63)ng/L、(9.89±2.42)mol/mL、(242.39±13.17)ng/mL、(242.39±13.17)ng/mL,均低于对照组[(31.40±5.04)ng/L、(14.69±3.27)mol/mL、(291.45±15.19)ng/mL、(50.42±9.81)ng/mL],差异均有统计学意义(P<0.05)。治疗后,观察组FFA、ApoB、甘油三酯水平分别为(421.60±40.33)μmol/L、(1.08±0.10)mmol/L、(5.28±1.03)mmol/L,均低于对照组[(529.43±42.61)μmol/L、(1.24±0.13)mmol/L、(9.14±1.79)mmol/L],差异均有统计学意义(P<0.05)。治疗后观察组APACHEⅡ评分为(10.49±1.61)分,低于对照组[(14.63±2.17)分],住院时间为(13.40±1.72)d,短于对照组[(17.06±1.80)d],差异均有统计学意义(P<0.05)。结论血脂康胶囊联合非诺贝特胶囊治疗高脂血症性胰腺炎可调节血液流变学指标水平,改善机体炎症状态及血脂代谢,提高整体疗效,控制病情,缩短患者住院时间,值得推广。